Hospital readmissions in children with new-onset infantile epileptic spasms syndrome.


Journal

Epilepsia open
ISSN: 2470-9239
Titre abrégé: Epilepsia Open
Pays: United States
ID NLM: 101692036

Informations de publication

Date de publication:
06 2023
Historique:
received: 12 01 2023
accepted: 09 02 2023
medline: 5 6 2023
pubmed: 16 2 2023
entrez: 15 2 2023
Statut: ppublish

Résumé

To describe inpatient resource use in the 2 years following infantile epileptic spasms syndrome (IESS) diagnosis, examine the association between clinical/demographic variables and incidence of readmission, and identify risk factors/reasons for frequent readmissions. Retrospective cohort analysis of readmissions (scheduled/unscheduled) within the first 2 years following IESS diagnosis, details of readmissions (number/time between rehospitalizations, and length of stay), demographic/clinical variables, and reasons for readmissions were collected. Negative binomial regression analysis evaluated associations between incidence of readmissions (both scheduled/unscheduled and unscheduled alone) and demographic/clinical factors. Logistic regression assessed the risk of having recurrent readmissions (≥5 readmissions). Among 93 (60% males) new-onset IESS patients, there were 394 readmissions (56% scheduled and 44% unscheduled) within 2-years following IESS diagnosis. Mean length of stay was 3.5 days (SD: 5.9). Readmissions occurred in 82 patients (88%) and 37 (40%) experienced ≥5 readmissions. On multivariate regression analysis, readmissions were increased with use of multiple first-line treatments for IESS (P = 0.006), technology assistance (P ≤ 0.001), and multispecialty care (P = 0.01); seizure freedom (P = 0.015) and known etiology (P = 0.011) lowered the incidence of readmissions. Examining unscheduled readmissions separately, increased readmissions occurred with public insurance (P = 0.013), technology use (P ≤ 0.0.001), and multispecialty care (P = 0.013); seizure freedom decreased unscheduled readmissions (P = 0.006). Technology assistance (G-tube, NG tube, VP shunt, and tracheostomy use) increased the odds (P = 0.007) for recurrent readmissions. Reasons for readmissions included EEG monitoring (protocol driven for verification of IESS remission/characterization of events/EEG surveillance/presurgical monitoring) (51%), acute medical issues (21%), and seizure exacerbation (15%). Protocol-driven readmissions declined an estimated 52% following protocol modification during the study. In the 2 years following IESS diagnosis, there is substantial inpatient resource use with nearly 40% experiencing ≥5 readmissions (mostly epilepsy related). Since readmissions are increased by intrinsic patient characteristics such as medical complexity (technology use and multispecialty care) or epilepsy-related issues, the preventability of readmissions is uncertain, except for protocol-driven ones.

Identifiants

pubmed: 36790214
doi: 10.1002/epi4.12711
pmc: PMC10235577
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

444-455

Informations de copyright

© 2023 The Authors. Epilepsia Open published by Wiley Periodicals LLC on behalf of International League Against Epilepsy.

Références

Epileptic Disord. 2004 Mar;6(1):31-40
pubmed: 15075066
J Perinatol. 2018 Jun;38(6):734-741
pubmed: 29449613
Epilepsia. 2018 Dec;59(12):2231-2239
pubmed: 30395353
Hosp Pediatr. 2015 Nov;5(11):602-4
pubmed: 26526809
Neurology. 2018 Jan 9;90(2):67-73
pubmed: 29247076
Pediatr Neurol. 2019 Apr;93:11-16
pubmed: 30704869
Epilepsia. 2010 Oct;51(10):2175-89
pubmed: 20608959
JAMA. 2013 Jan 23;309(4):372-80
pubmed: 23340639
Epilepsia. 2016 Nov;57(11):1834-1842
pubmed: 27615012
Epilepsy Res. 2021 Oct;176:106733
pubmed: 34333373
Pediatr Neurol. 2019 Oct;99:16-22
pubmed: 31331669
Neurology. 2019 Apr 16;92(16):e1926-e1932
pubmed: 30894440
Epilepsia. 2022 Jun;63(6):1349-1397
pubmed: 35503712
Epilepsy Res. 2014 Mar;108(3):576-86
pubmed: 24447611
JAMA. 2011 Feb 16;305(7):682-90
pubmed: 21325184
J Pediatr. 2011 Aug;159(2):284-90
pubmed: 21429511
Epilepsia Open. 2021 Dec;6(4):714-719
pubmed: 34524734
Epilepsia Open. 2018 Oct 23;3(Suppl Suppl 2):143-154
pubmed: 30564773
Pediatr Neurol. 2020 Mar;104:23-29
pubmed: 31911027
Epilepsia. 2011 Apr;52(4):746-52
pubmed: 21320111
Epilepsia. 2016 Mar;57(3):455-63
pubmed: 26785359
Dev Med Child Neurol. 2001 Oct;43(10):658-67
pubmed: 11665822
Pediatr Neurol. 2003 Apr;28(4):285-91
pubmed: 12849882
PLoS Med. 2012 Jan;9(1):e1001158
pubmed: 22272190
Adv Ther. 2016 Aug;33(8):1293-304
pubmed: 27324137
Epilepsia. 2015 Aug;56(8):1185-97
pubmed: 26122601
J Perinatol. 2022 May;42(5):624-630
pubmed: 34815520
J Child Neurol. 2016 Feb;31(2):164-9
pubmed: 25999302
Epilepsia Open. 2023 Jun;8(2):444-455
pubmed: 36790214
Pediatrics. 2010 Oct;126(4):647-55
pubmed: 20855394
Minerva Pediatr. 2020 Jun 05;:
pubmed: 32508074
Dev Med Child Neurol. 2012 Oct;54(10):938-44
pubmed: 22845753
Pediatr Neurol. 2018 May;82:13-18
pubmed: 29610033
Lancet Neurol. 2005 Nov;4(11):712-7
pubmed: 16239177
Epilepsia. 2012 Feb;53(2):291-300
pubmed: 22221191
Lancet Child Adolesc Health. 2018 Oct;2(10):715-725
pubmed: 30236380
Epilepsy Behav. 2014 Mar;32:135-41
pubmed: 24561658
Pediatr Neurol. 2020 Jul;108:93-98
pubmed: 32299746
BMJ. 2002 Oct 26;325(7370):961-4
pubmed: 12399352
J Pediatr. 2004 Jun;144(6):799-803
pubmed: 15192629
Epilepsia. 2010 May;51(5):874-82
pubmed: 20002149
Epilepsia. 2008 Sep;49(9):1504-9
pubmed: 18410363

Auteurs

Chellamani Harini (C)

Division of Epilepsy and Clinical Neurophysiology, Department of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

Christopher J Yuskaitis (CJ)

Division of Epilepsy and Clinical Neurophysiology, Department of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

Avantika Singh (A)

Division of Epilepsy and Clinical Neurophysiology, Department of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

Trevor McHugh (T)

Division of Epilepsy and Clinical Neurophysiology, Department of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

Shanshan Liu (S)

Biostatistics and Research Design Center, Institutional Centers for Clinical and Translational Research, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

Michelle DeLeo (M)

Division of Epilepsy and Clinical Neurophysiology, Department of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

Nishtha Gupta (N)

Division of Epilepsy and Clinical Neurophysiology, Department of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

Candice Marti (C)

Division of Epilepsy and Clinical Neurophysiology, Department of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

Bo Zhang (B)

Biostatistics and Research Design Center, Institutional Centers for Clinical and Translational Research, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Department of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

Mark H Libenson (MH)

Division of Epilepsy and Clinical Neurophysiology, Department of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

Jay G Berry (JG)

Complex Care, Division of General Pediatrics, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH